...
首页> 外文期刊>Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry >Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment.
【24h】

Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment.

机译:哌醋甲酯通过多巴胺能机制改变基底神经节神经降压素系统:与可卡因治疗的比较。

获取原文
获取原文并翻译 | 示例

摘要

Methylphenidate (MPD) is a psychostimulant widely used to treat behavioral problems such as attention deficit hyperactivity disorder. MPD competitively inhibits the dopamine (DA) transporter. Previous studies demonstrated that stimulants of abuse, such as cocaine (COC) and methamphetamine differentially alter rat brain neurotensin (NT) systems through DA mechanisms. As NT is a neuropeptide primarily associated with the regulation of the nigrostriatal and mesolimbic DA systems, the effect of MPD on NT-like immunoreactivity (NTLI) content in several basal ganglia regions was assessed. MPD, at doses of 2.0 or 10.0 mg/kg, s.c., significantly increased the NTLI contents in dorsal striatum, substantia nigra and globus pallidus; similar increases in NTLI were observed in these areas after administration of COC (30.0 mg/kg, i.p.). No changes in NTLI occurred within the nucleus accumbens, frontal cortex and ventral tegmental area following MPD treatment. In addition, the NTLI changes in basal ganglia regions induced by MPD were prevented when D(1) (SCH 23390) or D(2) (eticlopride) receptor antagonists were coadministered with MPD. MPD treatment also increased dynorphin (DYN) levels in basal ganglia structures. These findings provide evidence that basal ganglia, but not limbic, NT systems are significantly affected by MPD through D(1) and D(2) receptor mechanisms, and these NTLI changes are similar, but not identical to those which occurred with COC administration. In addition, the MPD effects on NT systems are mechanistically distinct from the effects of methamphetamine.
机译:哌醋甲酯(MPD)是一种精神刺激药,广泛用于治疗行为问题,例如注意力不足过动症。 MPD竞争性抑制多巴胺(DA)转运蛋白。先前的研究表明,可卡因(COC)和甲基苯丙胺等滥用刺激剂通过DA机制差异性改变了大鼠脑神经降压素(NT)系统。由于NT是一种主要与调节黑质纹状体和中脑边缘DA系统相关的神经肽,因此评估了MPD对几个基底神经节区域NT样免疫反应(NTLI)含量的影响。皮下注射MPD剂量为2.0或10.0 mg / kg,可显着增加背侧纹状体,黑质和苍白球的NTLI含量;服用COC(30.0 mg / kg,i.p.)后,这些区域的NTLI也有类似的增加。 MPD治疗后,伏隔核,额叶皮层和腹侧被盖区域内NTLI均未发生变化。此外,当D(1)(SCH 23390)或D(2)(依替普利)受体拮抗剂与MPD共同使用时,可以防止MPD诱导的基底节区NTLI变化。 MPD治疗还会增加基底神经节结构中的强啡肽(DYN)水平。这些发现提供了证据,表明基底神经节而非边缘NT系统受MPD通过D(1)和D(2)受体机制的显着影响,并且这些NTLI变化相似,但与COC给药时发生的变化不同。此外,MPD对NT系统的作用在机理上不同于甲基苯丙胺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号